Daily close, T-120 (12/11/24) through T+5. Run-up high $98.3 on 5/5/25, low $82.73 on 1/20/25 (T-120 to T-1). FDA decision 5/28/25. Historical price action, not a forecast.
Positioning before the decision
On May 14, 2025, 14 days before the decision date, at-the-money options priced a move of ±6.5% through Jun 20, 2025 (the first listed expiry after the decision; ATM implied volatility 26%). The stock closed -1.5% at the first close across the decision and -1.5% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was TRYPTYR (acoltremon ophthalmic solution) 0.003% approved by the FDA?
Yes. The FDA approved the application for TRYPTYR (acoltremon ophthalmic solution) 0.003% on May 28, 2025. The primary source is linked on this page.
What was TRYPTYR (acoltremon ophthalmic solution) 0.003% under FDA review for?
The application covered Dry eye disease (DED). The FDA approved the application on May 28, 2025.
How did ALC stock react to the FDA decision?
On the decision day ALC moved -1.5%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.